Show simple item record

dc.contributor.authorVásquez, Ximena
dc.contributor.authorSánchez-Gómez, Pilar 
dc.contributor.authorPalma, Verónica
dc.date.accessioned2021-08-26T19:00:27Z
dc.date.available2021-08-26T19:00:27Z
dc.date.issued2021-07-31
dc.identifier.citationInt J Mol Sci . 2021 ;22(15):8248.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/13320
dc.description.abstractGlioblastoma (GBM) is the most aggressive and common primary tumor of the central nervous system. It is characterized by having an infiltrating growth and by the presence of an excessive and aberrant vasculature. Some of the mechanisms that promote this neovascularization are angiogenesis and the transdifferentiation of tumor cells into endothelial cells or pericytes. In all these processes, the release of extracellular microvesicles by tumor cells plays an important role. Tumor cell-derived extracellular microvesicles contain pro-angiogenic molecules such as VEGF, which promote the formation of blood vessels and the recruitment of pericytes that reinforce these structures. The present study summarizes and discusses recent data from different investigations suggesting that Netrin-1, a highly versatile protein recently postulated as a non-canonical angiogenic ligand, could participate in the promotion of neovascularization processes in GBM. The relevance of determining the angiogenic signaling pathways associated with the interaction of Netrin-1 with its receptors is posed. Furthermore, we speculate that this molecule could form part of the microvesicles that favor abnormal tumor vasculature. Based on the studies presented, this review proposes Netrin-1 as a novel biomarker for GBM progression and vascularization.es_ES
dc.description.sponsorshipThis work was supported by: FONDECYT # 1140697 (VP) and Ministerio de Ciencia, Innovación y Universidades and FEDER funds (RTI2018-093596) (PSG).es_ES
dc.language.isoenges_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectNetrin-1es_ES
dc.subjectExosomeses_ES
dc.subjectGlioblastomaes_ES
dc.subjectNeovascularizationes_ES
dc.subjectPericyteses_ES
dc.subjectTransdifferentiationes_ES
dc.titleNetrin-1 in Glioblastoma Neovascularization: The New Partner in Crime?es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID34361013es_ES
dc.format.volume22es_ES
dc.format.number15es_ES
dc.format.page8248es_ES
dc.identifier.doi10.3390/ijms22158248es_ES
dc.contributor.funderMinisterio de Ciencia, Innovación y Universidades (España) 
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) 
dc.contributor.funderFondo Nacional de Desarrollo Científico y Tecnológico (Chile) 
dc.description.peerreviewedes_ES
dc.identifier.e-issn1422-0067es_ES
dc.relation.publisherversionhttps://doi.org/10.3390/ijms22158248es_ES
dc.identifier.journalInternational Journal of Molecular Scienceses_ES
dc.repisalud.centroISCIII::Instituto de Investigación de Enfermedades Rarases_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RTI2018-093596es_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional